GIVE Teaming Profiles

This page is designed to help facilitate connections between prospective proposers, which ARPA-H anticipates will be necessary to achieve the goals of the Genetic Medicines and Individualized Manufacturing (GIVE) program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal.

If either you or your organization are interested in teaming, please create a profile via the ARPA-H Solutions Portal linked below. Your details will then be added to this page, which is publicly available.

Create a Teaming Profile

Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here or the accuracies of the statements made therein. Submissions to the teaming profiles list are reviewed and updated periodically.

GIVE Teaming Profiles

To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.

Xuan Wang	Virginia Tech	xuanw@vt.edu	Blacksburg, VA	We have a recent pitch video on “Towards Intelligent and Resilient U.S. Pharmaceutical Supply Chains via Multi-Agent AI” has been deemed Awardable by the DARPA ERIS Marketplace.	Manufacturing partners	TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control
Karen Weisinger	Cell X Technologies	kweisinger@cellxtechnologies.com	Woburn, MA	Cell X brings a fully, automated solution for adherent cell manufacturing, anchored by it's proprietary Celligent system and C-Suite software platform, together enabling low variability and data-rich workflows that enable IND submissions. Using the Celligent, we have a strong track record of generating iPSC cell lines as well as various types of target cells from iPSCs in both research and GMP settings, making our platform especially suitable for the automation portion of the GIVE initiative.	We seek a therapeutic developer partner for the GIVE initiative to automate processes on our system and create reliable therapeutics. Our goal is to collaborate on an innovative therapy that truly benefits from automation, where the synergy of our technologies and expertise is greater than the sum of its parts.	TA2: Integrated Quality Control
Karen Weisinger	Cell X Technologies	kweisinger@cellxtechnologies.com	WOBURN, MA	Cell X brings a fully, automated solution for adherent cell manufacturing, anchored by it's proprietary Celligent system and C-Suite software platform, together enabling low variability and data-rich workflows that enable IND submissions. Using the Celligent, we have a strong track record of generating iPSC cell lines as well as various types of target cells from iPSCs in both research and GMP settings, making our platform especially suitable for the automation portion of the GIVE initiative.	We seek a therapeutic developer partner for the GIVE initiative to automate processes on our system and create reliable therapeutics. Our goal is to collaborate on an innovative therapy that truly benefits from automation, where the synergy of our technologies and expertise is greater than the sum of its parts.	TA2: Integrated Quality Control
Graham Taylor	Helix Biotech, Inc.	graham@helix-biotech.com	Knoxville, TN	Helix Biotech specializes in custom DNA/RNA synthesis and the development and GMP manufacturing of nucleic acids, lipid nanoparticles (LNPs), liposomes, and hybrid nanoparticles.	Open to teaming for any needs	TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control
John Cooke	Houston Methodist Research Institute	jpcooke@houstonmethodist.org	Houston, TX	Our Center for RNA Therapeutics generates fundamental insights in RNA Biology, translating them into transformative therapies for patients. We have novel platforms for circular RNA and more stable mRNA structures with high translational efficiency; and generate AI algorithms for computational RNA biology and therapeutics. Our RNACore synthesizes, purifies, encapsulates, and validates clinical grade mmRNA and circular RNA in ISO7 clean rooms with a cGMP trained team for FDA-approved INDs.	To our knowledge, we are the only AMC capable of generating mmRNA and circular RNA drugs for clinical trials; and have great expertise in synthesis, purification, encapsulation and QC (having made about 600 constructs for about 175 clients; primarily research grade). We are looking for scientists that have expertise in mmRNA-based gene therapy; as well as a medtech company that intends to develop a deployable manufacturing unit for hospital-based personalized mRNA (or circRNA) therapies	TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control
Melik Demirel	Penn State University	melikdemirel@gmail.com	university park, PA	high-throughput assays for RNA biomanufacturing	companies or institutes with next generation therapies expertise	TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control
Krishanu Saha	University of Wisconsin-Madison	ksaha@wisc.edu	Madison, WI	Developing and clinically implementing innovative RNA-based CRISPR therapies, cancer vaccines, and RNA-modified cell therapies for rare pediatric and adult diseases.	UW-Madison is open to all suggestions for collaboration in this area.	TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control
Freddy Nguyen	Nine Diagnostics	freddy.nguyen@ninediagnostics.xyz	Cambridge, MA	Nine Diagnostics develops an AI-enabled nanosensor platform for real-time, in-process quality control in genetic medicine and cell therapy manufacturing. Our carbon-nanotube optical sensors provide rapid, multiplexed proteomic and metabolomic readouts from microliter samples, enabling continuous monitoring of product consistency, cell health, and process stability across distributed biomanufacturing workflows.	We seek partners developing RNA, cell, or gene therapy manufacturing systems who need integrated, automated quality control. Ideal collaborators include bioreactor, process, or analytical platform developers interested in embedding real-time nanosensor feedback to reduce batch variability, accelerate release testing, and enable distributed or on-demand manufacturing.	TA2: Integrated Quality Control, TA1: Automated RNA Manufacturing
Minghong Zhong	GeneLancet Biosciences, INC	MINGHONG.ZHONG@genelancetbio.com	Doylestown, PA	GeneLancet (www.genelancetbio.com) advances precision gene editing with its proprietary LgRNA technology. LgRNAs outperform classical guides like sgRNAs and pegRNAs in key areas: superior product quality for enhanced safety, optimized drug-like properties for better delivery, and unmatched scalability for efficient manufacturing.	We seek collaborations in all CRISPR platforms. Check out our guide RNA white paper (https://www.genelancetbio.com/genelancet-guide-rna-white-paper).	TA1: Automated RNA Manufacturing, TA2: Integrated Quality Control
Aaron Leopold	NTxBio	aaron.leopold@ntxbio.com	Rio Rancho, NM	NTxBio has an automated and fully-closed benchtop system for continuous flow RNA synthesis and purification. The system produces high-integrity, high-purity mRNA or saRNA up to 11.5+kb and is designed for personalized medicine with instant changeover between constructs.	We seek therapeutic partners as well as upstream DNA synthesis and downstream encapsulation partners to create an integrated end-to-end manufacturing system.	TA1: Automated RNA Manufacturing
Marc Taraban	University of Maryland Baltimore	mtaraban@rx.umaryland.edu	Rockville, MD	PAT for noninvasive final product inspection and in-line process monitoring for cell and gene therapy products. Examples include assessing empty/full ratio for viral vector products in gene therapy and cell count and viability in cell therapy. The technology, wNMR, involves no sample preparation and no reagents (e.g., https://pubs.acs.org/doi/10.1021/acs.analchem.1c04088)	Manufacturers of cell and gene therapy products.	TA2: Integrated Quality Control